This is a preview of subscription content, log in via an institution to check access.
Reference
Nakashima I, et al. Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan. Therapeutic Advances in Neurological Disorders 16: 30 Jun 2023. Available from: URL: https://journals.sagepub.com/doi/10.1177/17562864231181177
Rights and permissions
About this article
Cite this article
Eculizumab. Reactions Weekly 1974, 141 (2023). https://doi.org/10.1007/s40278-023-46152-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-46152-x